IOVANCE BIOTHERAPEUTICS INC's ticker is IOVA and the CUSIP is 462260100. A total of 250 filers reported holding IOVANCE BIOTHERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is 0.21 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $491,580 | +8.9% | 80,455 | +13.9% | 0.25% | +38.3% |
| Q4 2022 | $451,485 | -55.3% | 70,655 | +16.4% | 0.18% | -31.2% |
| Q1 2022 | $1,011,000 | -1.9% | 60,720 | +12.5% | 0.27% | +6.8% |
| Q4 2021 | $1,031,000 | -68.1% | 53,981 | -58.8% | 0.25% | -66.2% |
| Q3 2021 | $3,233,000 | -22.5% | 131,098 | -18.2% | 0.74% | -35.8% |
| Q2 2021 | $4,173,000 | -57.6% | 160,362 | -48.4% | 1.15% | -55.3% |
| Q1 2021 | $9,835,000 | +290.9% | 310,649 | +472.9% | 2.56% | +182.7% |
| Q4 2020 | $2,516,000 | +315.9% | 54,221 | +168.3% | 0.91% | +231.0% |
| Q1 2020 | $605,000 | -87.0% | 20,207 | -88.0% | 0.27% | -81.4% |
| Q4 2019 | $4,665,000 | +197.9% | 168,546 | +95.8% | 1.47% | +161.6% |
| Q3 2019 | $1,566,000 | -63.1% | 86,069 | -50.3% | 0.56% | -66.4% |
| Q2 2019 | $4,248,000 | +50.9% | 173,238 | -45.6% | 1.68% | +12.6% |
| Q4 2018 | $2,816,000 | +3.4% | 318,185 | +31.4% | 1.49% | +22.8% |
| Q3 2018 | $2,724,000 | – | 242,169 | – | 1.21% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Fairmount Funds Management LLC | 565,890 | $26,257,000 | 9.39% |
| Consonance Capital Management LP | 1,710,803 | $79,381,000 | 7.41% |
| GREAT POINT PARTNERS LLC | 917,427 | $42,569,000 | 6.91% |
| Avoro Capital Advisors LLC | 7,500,000 | $348,000,000 | 5.99% |
| Ghost Tree Capital, LLC | 500,000 | $23,200,000 | 5.17% |
| FRAZIER MANAGEMENT LLC | 1,312,999 | $60,923,000 | 4.69% |
| Perceptive Advisors | 9,166,304 | $425,316,000 | 4.56% |
| Ally Bridge Group (NY) LLC | 360,000 | $16,704,000 | 2.86% |
| Orbimed Advisors | 6,645,100 | $308,333,000 | 2.70% |
| ACUTA CAPITAL PARTNERS, LLC | 164,800 | $7,647,000 | 2.08% |